<DOC>
	<DOC>NCT01543503</DOC>
	<brief_summary>This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy. Data will be collected for 52 weeks.</brief_summary>
	<brief_title>An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of rheumatoid arthritis Nonrespondent or intolerant to nonbiologic diseasemodifying antirheumatic drug (DMARD) therapy Patient has been prescribed a first biologic therapy up to 6 weeks prior to the inclusion visit, irrespective of the treatment prescribed Patients whose first biologic therapy is given as part of a clinical trial studying rheumatoid arthritis (RA) treatment Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months Patients whose first biologic is rituximab, abatacept or anakinra. Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>